基于粪便DNA甲基化检测的结直肠癌早期诊断
Journal: Basic Medical Theory Research DOI: 10.12238/bmtr.v6i3.7511
Abstract
粪便DNA甲基化检测是一种基于DNA甲基化在正常细胞和癌变细胞之间差异的结直肠癌(Colorectal Cancer, CRC)早期诊断方法。该技术简单、无创伤,具有较高的敏感度和特异度。用于检测的标志分子,包括隔膜蛋白9(Septin 9 gene, SEPT9)、波形蛋白(Human Vimentin, VIM)、分泌型卷曲相关蛋白2(Secreted Frizzled Related Protein 2, SFRP2)等已在一些地区被批准用于筛查和诊断,而其他的标志分子如人肿瘤高甲基化1基因(Hypermethylated in Cancer1,HIC-1)、组织因子通道抑制因子2(Tissue Factor Pathway Inhibitor2,TFPI2)和黏结蛋白聚糖2(Syndecan-2,SDC2)也显示出了潜在价值。尽管仍需要更多的临床验证,但粪便DNA甲基化检测为提高结直肠癌的早期筛查检出率和早期治疗率提供了重要工具。
Keywords
结直肠癌；早期诊断；粪便DNA甲基化检测；黏结蛋白聚糖2
Funding
湖北省重点研发计划项目(社会发展领域)(No.2022BCA018)及工业微生物省部共建协同创新中心开放课题(2022KF16)。
Full Text
PDF - Viewed/Downloaded: 0 TimesReferences
[1] SUNG H,FERLAY J,SIEGEL RL,etal.Global Cancer Statist ics 2020:GLOBOCAN Estimates of Incidence and Mortality Worl dwide for 36 Cancers in 185 Countries [J].CA Cancer J Clin, 2021,71(3):209-249.
[2] LOEHRERSR P. Colon Cancer Survival Rates With the New American Joint Committee on Cancer Sixth Edition Staging[J]. Yearbook of Oncology, 2006,2006:280-281.
[3] KNUDSEN, AMY B, NABER, et al. Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies Modeling Study for the US Preventive Services Task Force[J]. JAMA: the Journal of the American Medical Association, 2016; 315(23):2595-2609.
[4] Hospital Authority of National Health Commission of the People's Republic of China, Chinese Society of Oncology Chinese Medical Association.中国结直肠癌诊疗规范 (2023版)[J].消化肿瘤杂志(电子版),2023,15(03):177-206.
[5] 中华医学会检验医学分会分子诊断学组.早期结直肠癌和癌前病变实验诊断技术中国专家共识[J].中华检验医学杂志,2021,44(5):372-380.
[6] 国家消化系统疾病临床医学研究中心(上海),国家消化道早癌防治中心联盟,中华医学会消化内镜学分会,等.中国早期结直肠癌筛查流程专家共识意见(2019,上海)[J].中华消化内镜杂志,2019,36(10):709-719.
[7] CIARDIELLO,F.,CIARDIELLO,D.,MARTINI,G,etal.Clinicalmanagement of metastatic colorectal cancer in the era of precisi on medicine[J].CA A Cancer J Clin,2022,72:372-401.
[8] OSBORN NK, AHLQUIST DA. Stool screening for colorectal cancer:molecular approaches[J].Gastroenterology, 2005;128(1): 1286-1293.
[9] TZKOWITZ S,BRAND R,JANDORF L,etal.A simplified, noninv asive stool DNA test for colorectal cancer detection[J]. Amer ican Journal of Gastroenterology,2008,103(11):2862-2870.
[10] AHLQUIST DA, TAYLOR WR, MAHONEY DW, et al. The Stool DNA Test is More Accurate than the Plasma Septin 9 Test in Detecting Colorectal Neoplasia[J]. Clinical gastroenterology and hepatology: the official clinical practice journal of the American GastroenterologicalAssociation,2012,10(3):272-277.
[11] AHLQUIST DA, ZOU H, DOMANICO M, et al. Next-Generat ion Stool DNA Test Accurately Detects Colorectal Cancer and Large Adenomas[J]. Gastroenterology,2012,142(2):248-256.
[12] USPSTF, KIRSTEN BD, GROSSMAN DC, et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recomm endation Statement[J].JAMA.2016;315(23):2564-2575.
[13] REX DK, BOLAND CR, DOMINITZ JA, et al. Colorectal Can cer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer [J].Gastroenterology.2017;153(1):307-323.
[14] PROVENZALE D,GUPTA S,AHNEN DJ,et al. NCCN Guidelines Insights:Colorectal Cancer Screening, Version 1.2018[J].Jour nal of the National Comprehensive Cancer Network: JNCCN. 2018;16(8):939-949.
[15] WOLF AMD, FONTHAM ETH, CHURCH TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society[J]. CA Cancer J Clin. 2018;68(4):250-281.
[16] SAU YK, MIZUHO N, ATSUYA M, et al. Genetic and nonge netic mechanisms for colorectal cancer evolution[J]. Cancer Science.2023;114:3478-3486.
[17] ZHONG J, ZHAO M, MA Y,et al. UCHL1 acts as a colorectalcancer oncogene via activation of the β-catenin/TCF pathway through its deubiquitinating activity[J].International Journ al of Molecular Medicine,2012,30(2):430-436.
[18] LI J,MA X, CHAKRAVARTI D, et al. Genetic and biological hallmarks of colorectal cancer[J]. Genes & Development, 2021, 35(11-12):787-820.
[19] BARDHAN K,LIU K．Epigenetics and Colorectal Cancer Pathogenesis[J].Cancers,2013,5(2):676-713.
[20] GOEL A, BOLAND CR, et al. Epigenetics of Colorectal Cancer[J]. Gastroenterology,2012.143(6):1442-1460.
[21] SUZUKI H, WATKINS DN, JAIR KW, et al. Epigenetic inact ivation of SFRP genes allows constitutive WNT signaling in colorectal cancer[J].Nature Genetics,2004,36(4):417-422.
[22] ZHANG H, ZHU YQ, WU YQ, et al. Detection of promoter hypermethylation of Wnt antagonist genes in fecal samples for diagnosis of early colorectal cancer[J]. World J Gastroenterol,2014,20(20):6329-6335.
[23] 徐正,颜宏利.粪便基因甲基化检测在结直肠癌早期诊断中的研究进展[J].医学综述,2020,26(11):2177-2187
[24] LENHARD K, BOMMER GT, ASUTAY S, et al. Analysis of promoter methylation in stool: A novel method for the detec tion of colorectal cancer[J].Clinical Gastroenterology & Hepa tology,2005,3(2):142-149.
[25] SATELLI A, LI S. Vimentin in cancer and its potential as a molecular target for cancer therapy[J].Cellular and Mole cular Life Sciences,2011,68(18):3033-3046.
[26] CHEN WD, HAN ZJ, SKOLETSKY J, et.al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene[J].Journal of the National Cancer Institute, 2005,97(15):1124-1132.
[27] NED RM, MELILLO S, MARRONE M. Fecal DNA testing for colorectal cancer screening:the ColoSure™ test[J]. PLoS Curre nts,2011,3:RRN1220.
[28] SIERKO E, WOJTUKIEWICZ MZ, KISIEL W. The role of tiss ue factor pathway inhibitor-2 in cancer biology[J]. Seminars in Thrombosis and Hemostasis,2007,33(7):653-659.
[29] GLOCKNER SC, DHIR M, Yi JM, et al. Methylation of TFPI2 in Stool DNA: A Potential Novel Biomarker for the Detection of Colorectal Cancer[J].Cancer Research,2009,69(11): 4691-4699.
[30] MYTILINAIOU M, NIKITOVIC D, BERDIAKI A, et al. Emerg ing roles of syndecan 2 in epithelial and mesenchymal cancer progression[J]. IUBMB Life,2017.69(11):824-833.
[31] OH T,KIM N,MOON Y,etal.etal.Genome-wide identificati on and validation of a novel methylation biomarker, SDC2, for blood-based detection of colorectal cancer[J].Journal of Mol ecular Diagnostics, 2013, 15(4):498-507.
[32] YOON DH, TAE JO, TAE-HA C, et al. Early detection of colorectal cancer based on presence of methylated syndecan -2 (SDC2) in stool DNA[J]. Clinical epigenetics,2019,11(1):51.
[33] 肖著军,王新颖,李丙生,等.联合检测vimentin和SFRP2甲基化在大肠癌筛查中的应用评价 [J].现代消化的介入诊疗,2014,19(1):13-20．
[34] KANGY,CAOF, CHANG W, et al. Gene methylation in stool for the screening of colorectal cancer and pre-malignant lesions[J]. Chinese journal of gastrointestinal surgery, 2011,14(1):52-56．
[35] 黄子懿,贺延新,陈存海.粪便多基因甲基化联合检测在CRC及癌前病变诊断中的价值[J].肿瘤研究与临床,2022,34(4):7.
[36] LIB,LIUS,GAOY,et.al.Combined detection of SDC2/ADHFE1 /PPP2R5C methylation in stool DNA for colorectal cancer scree ning[J].Journal of Cancer Research and Clinical Oncology, 2023,149(12):10241-10253
[37] 柏愚,刘晶,康倩.联合检测SDC2和SFRP2甲基化在结直肠癌筛查中的价值[J].中华消化内镜杂志,2019,36(6):427-432.
[38] ZHANGL,DONGL,LuC,etal.MethylationofSDC2/TFPI2andItsDiagnosticValueinColorectalTumorousLesions[J].FrontiersinMolecularBiosciences,2021,8
[39] 韩冰,申玉翠,王慧,等.粪便Vimentin和SFRP2甲基化在结直肠癌筛查中的作用[J].胃肠病学和肝病学杂志,2020,29(5):561-566.
[40] LINDGE,AHLQUIST T, KOLBERG M, et al. Hypermethylated MAL gene-a silent marker of early colon tumorigenesis[J].Journal of Translational Medicine,6,1(2008-03-17), 2008, 6(1):13-24.
[41] SHEN L, KONDO Y, HAMILTON SR, et al. p14 methylation in human colon cancer is associated with microsatellite instability and wild-type p53[J].Gastroenterology, 2003, 124 (3):626-633.
[42] KAZUYA M,KAZUYUKI K,YOSHINORI I,etal. Hypermethylati on of the CDKN2A gene in colorectal cancer is associated with shorter survival[J]. Oncology Reports, 2003, 10(4): 935-938.
[43] ESTELLER M, HAMILTON SR, BURGER PC, et al. Inactivation of the DNA Repair Gene O6-Methylguanine-DNA Methyltransferase by Promoter Hypermethylation is a Common Event in Primary Human Neoplasia[J]. Cancer Research, 1999,59(4):793-797.
[44] FAN J, LI J, GUO S, et al. Genome-wide DNA methylation profiles of low- and high-grade adenoma reveals potential biomarkers for early detection of colorectal carcinoma[J]. Clinical Epigenetics,2020,12(1): 56
[45] SHEN Y, WANG D, YUAN T, et al. Novel DNA methylation biomarkers in stool and blood for early detection of colorec tal cancer and precancerous lesions[J]. Clinical Epigenetics, 2023,15(1).
[46] 国家食品药品监督管理总局医疗器械技术评审中心.体外诊断试剂产品注册技术评审报告:人类SDC2基因甲基化检测试剂盒(荧光PCR法)(CSZ1800035)[R/OL].[2018-11-13].https: //www.cmde.org.cn/CL0116/8094.html.
[47] MAL,QING,GAIF,etal.A novel method for early detecti on of colorectal cancer based on detection of methylation of two fragments of syndecan-2 (SDC2) in stool DNA[J]. BMC Gastroenterology,2022,22(1):1-10.
[48] SHI ZY, CHEN LP, LI BX, et al. Comparative analysis of different fecal DNA extraction methods[J]. Chinese Journal of Biotechnology,2022,38(9):3542-3550.
[49] WANG J, LIU S, WANG H, et al. Robust performance of a novel stool DNA test of methylated SDC2 for colorectal cancer detection: a multicenter clinical study[J]. Clinical Epigenetics,2020,12(1):162-174.
[50] WANG DY, HE KX, HUANG Y, et al. A New Method for the Detection of Colorectal Cancer and the Precancerous Lesions: Occult Blood Testing Combination with Promoter Methylation in the Fecal Sample[J].Journal of Cancer,2021,12(2): 335-342.
[51] IMPERIALE TF, RANSOHOFF DF, ITZKOWITZ SH, et al. Multitarget stool DNA testing for colorectal-cancer screening [J].The New England journal of medicine,2014,370(14):1287- 1297.
[52] 马志刚,朱晓麟,马丽红.基于多靶点粪便FIT-DNA联合检测技术的结直肠癌早期筛查结果分析[J].中华结直肠疾病电子杂志,2019,8(06):616-621.
[53] KATSMANE, ORLANSKI S, MARTIGNANO F, et al. Detecting cell-of-origin and cancer-specific methylation features of cell-free DNA from Nanopore sequencing[J]. Genome Biology, 2022,23(1):1-25.
[54] LEE I, RAZAGHI R, GILPATRICK T, et al. Simultaneous profiling of chromatin accessibility and methylation on huma n cell lines with nanopore sequencing[J]. Nature Methods, 2020,17,1191-1199.
[55] 贾哲,吴晓滨.肠道微生物群在肿瘤中的作用和机制研究进展[J].消化肿瘤杂志:电子版,2023,15(2):160-165.
[56] 陈星,姜泊,迪吉.肠道菌群对早期结直肠癌筛查的研究进展[J].消化肿瘤杂志:电子版,2022,14(3):262-267.
[57] EVELIEND, TANIS PJ, VLEUGELS JLA, et al. Colorectal cancer[J]. Lancet (London, England), 2020, 2019年394卷10207期:1467-1480.
[58] WILLETT CG, CHANG DT, CZITO BG, et al. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer[J].Nature2012.(5);487: 330-37.
[59] FENNELL LJ, JAMIESON S, MCKEONE D, et al. MLH1-93G/a polymorphism is associated with MLH1 promoter methylation and protein loss in dysplastic sessile serrated adenomas with BRAF V600E mutation[J]. Bmc Cancer,2018,18(1):35.
[60] FARZANEHFAR M, VOSSOUGHINIA H, JABINI R, et al. Evaluation of methylation of MGMT (O⁶-methylguanine-DNA methylt ransferase) gene promoter in sporadic colorectal cancer[J]. Dna & Cell Biology,2013,32(7):371-377.
[61] LEGGETT B, WHITEHALL V, Role of the serrated pathway in colorectal cancer pathogenesis[J].Gastroenterology, 2010, 138(6):2088-2100.
[62] 潘程宇,曹俊,季兴,等.实时荧光定量PCR和甲基化特异性PCR检测结直肠癌 APC、MLH1基因甲基化状态[J].胃肠病学,2011,16(002):77-81.
[63] 蔡克银,徐梅华,王晓.检测粪便DNA中hMLH1基因甲基化对老年性结直肠癌早期诊断的意义[J].联勤军事医学,2017,31(12):814-817.
[64] 高文仓,张月蒙.胰岛素样生长因子结合蛋白相关蛋白1基因甲基化检测联合粪便潜血定量试验在结直肠癌中的诊断价值[J].中国医药,2021,16(6):886-889.
[65] GUINNEYJ, DIENSTMANN R, WANG X, et al. The consensus molecular subtypes of colorectal cancer[J]. Nature medicine, 2015,21(11):1350-1356.
[66] LEE MS, MENTER DG, KOPETZ S. Right Versus Left Colon Cancer Biology: Integrating the Consensus Molecular Subtyp es[J].Journal of the National Comprehensive Cancer Network, 2017,15(3):411-419.
[67] SANO Y,BYEON JS,LI XB,et al. Colorectal cancer screen ing of the general population in East Asia[J]. Dig Endosc, 2016, 28(3):243-249.
[68] ISLAMI F,WARD EM,SUNG H,et al. Annual report to the nation on the status of cancer,part 1:national cancer stati stics[J],Journal of the National Cancer Institute,2021,113(12),1648-1669.
[69] XU JF, RONG L, GU F, et al. Asia-Pacific Colorectal Screening Score Combined with Stool DNA Test Improves the Detection Rate for Colorectal Advanced Neoplasms[J]. Clinical gastroenterology and hepatology: the official clinical prac tice journal of the American Gastroenterological Association, 2023,21(6):1627-1636.
[70] RUBIN J S, BARSHIISHAT-KUPPER M, FEROZE-MERZOUG F,et al. Secreted WNT antagonists as tumor suppressors: pro and con[J]. Frontiers in Bioscience, 2006,11(11):2093-2105.
[71] LEE JL, LIN CT, ChUEH LL, et al. Autocrine/paracrine SFRP2 induces cellular resistance to apoptosis: A possible mechanism of mammary tumorigenesis[J]. Journal of Biological Chemistry,2004,279(15):14602-14609.
[72] BOVOLENTA P, ESTEVE P, RUIZ JM, et al. Beyond Wnt inh ibition: new functions of secreted Frizzled-related proteins in development and disease[J].J Cell Sci,2008,121(Pt6):737-746.
[2] LOEHRERSR P. Colon Cancer Survival Rates With the New American Joint Committee on Cancer Sixth Edition Staging[J]. Yearbook of Oncology, 2006,2006:280-281.
[3] KNUDSEN, AMY B, NABER, et al. Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies Modeling Study for the US Preventive Services Task Force[J]. JAMA: the Journal of the American Medical Association, 2016; 315(23):2595-2609.
[4] Hospital Authority of National Health Commission of the People's Republic of China, Chinese Society of Oncology Chinese Medical Association.中国结直肠癌诊疗规范 (2023版)[J].消化肿瘤杂志(电子版),2023,15(03):177-206.
[5] 中华医学会检验医学分会分子诊断学组.早期结直肠癌和癌前病变实验诊断技术中国专家共识[J].中华检验医学杂志,2021,44(5):372-380.
[6] 国家消化系统疾病临床医学研究中心(上海),国家消化道早癌防治中心联盟,中华医学会消化内镜学分会,等.中国早期结直肠癌筛查流程专家共识意见(2019,上海)[J].中华消化内镜杂志,2019,36(10):709-719.
[7] CIARDIELLO,F.,CIARDIELLO,D.,MARTINI,G,etal.Clinicalmanagement of metastatic colorectal cancer in the era of precisi on medicine[J].CA A Cancer J Clin,2022,72:372-401.
[8] OSBORN NK, AHLQUIST DA. Stool screening for colorectal cancer:molecular approaches[J].Gastroenterology, 2005;128(1): 1286-1293.
[9] TZKOWITZ S,BRAND R,JANDORF L,etal.A simplified, noninv asive stool DNA test for colorectal cancer detection[J]. Amer ican Journal of Gastroenterology,2008,103(11):2862-2870.
[10] AHLQUIST DA, TAYLOR WR, MAHONEY DW, et al. The Stool DNA Test is More Accurate than the Plasma Septin 9 Test in Detecting Colorectal Neoplasia[J]. Clinical gastroenterology and hepatology: the official clinical practice journal of the American GastroenterologicalAssociation,2012,10(3):272-277.
[11] AHLQUIST DA, ZOU H, DOMANICO M, et al. Next-Generat ion Stool DNA Test Accurately Detects Colorectal Cancer and Large Adenomas[J]. Gastroenterology,2012,142(2):248-256.
[12] USPSTF, KIRSTEN BD, GROSSMAN DC, et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recomm endation Statement[J].JAMA.2016;315(23):2564-2575.
[13] REX DK, BOLAND CR, DOMINITZ JA, et al. Colorectal Can cer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer [J].Gastroenterology.2017;153(1):307-323.
[14] PROVENZALE D,GUPTA S,AHNEN DJ,et al. NCCN Guidelines Insights:Colorectal Cancer Screening, Version 1.2018[J].Jour nal of the National Comprehensive Cancer Network: JNCCN. 2018;16(8):939-949.
[15] WOLF AMD, FONTHAM ETH, CHURCH TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society[J]. CA Cancer J Clin. 2018;68(4):250-281.
[16] SAU YK, MIZUHO N, ATSUYA M, et al. Genetic and nonge netic mechanisms for colorectal cancer evolution[J]. Cancer Science.2023;114:3478-3486.
[17] ZHONG J, ZHAO M, MA Y,et al. UCHL1 acts as a colorectalcancer oncogene via activation of the β-catenin/TCF pathway through its deubiquitinating activity[J].International Journ al of Molecular Medicine,2012,30(2):430-436.
[18] LI J,MA X, CHAKRAVARTI D, et al. Genetic and biological hallmarks of colorectal cancer[J]. Genes & Development, 2021, 35(11-12):787-820.
[19] BARDHAN K,LIU K．Epigenetics and Colorectal Cancer Pathogenesis[J].Cancers,2013,5(2):676-713.
[20] GOEL A, BOLAND CR, et al. Epigenetics of Colorectal Cancer[J]. Gastroenterology,2012.143(6):1442-1460.
[21] SUZUKI H, WATKINS DN, JAIR KW, et al. Epigenetic inact ivation of SFRP genes allows constitutive WNT signaling in colorectal cancer[J].Nature Genetics,2004,36(4):417-422.
[22] ZHANG H, ZHU YQ, WU YQ, et al. Detection of promoter hypermethylation of Wnt antagonist genes in fecal samples for diagnosis of early colorectal cancer[J]. World J Gastroenterol,2014,20(20):6329-6335.
[23] 徐正,颜宏利.粪便基因甲基化检测在结直肠癌早期诊断中的研究进展[J].医学综述,2020,26(11):2177-2187
[24] LENHARD K, BOMMER GT, ASUTAY S, et al. Analysis of promoter methylation in stool: A novel method for the detec tion of colorectal cancer[J].Clinical Gastroenterology & Hepa tology,2005,3(2):142-149.
[25] SATELLI A, LI S. Vimentin in cancer and its potential as a molecular target for cancer therapy[J].Cellular and Mole cular Life Sciences,2011,68(18):3033-3046.
[26] CHEN WD, HAN ZJ, SKOLETSKY J, et.al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene[J].Journal of the National Cancer Institute, 2005,97(15):1124-1132.
[27] NED RM, MELILLO S, MARRONE M. Fecal DNA testing for colorectal cancer screening:the ColoSure™ test[J]. PLoS Curre nts,2011,3:RRN1220.
[28] SIERKO E, WOJTUKIEWICZ MZ, KISIEL W. The role of tiss ue factor pathway inhibitor-2 in cancer biology[J]. Seminars in Thrombosis and Hemostasis,2007,33(7):653-659.
[29] GLOCKNER SC, DHIR M, Yi JM, et al. Methylation of TFPI2 in Stool DNA: A Potential Novel Biomarker for the Detection of Colorectal Cancer[J].Cancer Research,2009,69(11): 4691-4699.
[30] MYTILINAIOU M, NIKITOVIC D, BERDIAKI A, et al. Emerg ing roles of syndecan 2 in epithelial and mesenchymal cancer progression[J]. IUBMB Life,2017.69(11):824-833.
[31] OH T,KIM N,MOON Y,etal.etal.Genome-wide identificati on and validation of a novel methylation biomarker, SDC2, for blood-based detection of colorectal cancer[J].Journal of Mol ecular Diagnostics, 2013, 15(4):498-507.
[32] YOON DH, TAE JO, TAE-HA C, et al. Early detection of colorectal cancer based on presence of methylated syndecan -2 (SDC2) in stool DNA[J]. Clinical epigenetics,2019,11(1):51.
[33] 肖著军,王新颖,李丙生,等.联合检测vimentin和SFRP2甲基化在大肠癌筛查中的应用评价 [J].现代消化的介入诊疗,2014,19(1):13-20．
[34] KANGY,CAOF, CHANG W, et al. Gene methylation in stool for the screening of colorectal cancer and pre-malignant lesions[J]. Chinese journal of gastrointestinal surgery, 2011,14(1):52-56．
[35] 黄子懿,贺延新,陈存海.粪便多基因甲基化联合检测在CRC及癌前病变诊断中的价值[J].肿瘤研究与临床,2022,34(4):7.
[36] LIB,LIUS,GAOY,et.al.Combined detection of SDC2/ADHFE1 /PPP2R5C methylation in stool DNA for colorectal cancer scree ning[J].Journal of Cancer Research and Clinical Oncology, 2023,149(12):10241-10253
[37] 柏愚,刘晶,康倩.联合检测SDC2和SFRP2甲基化在结直肠癌筛查中的价值[J].中华消化内镜杂志,2019,36(6):427-432.
[38] ZHANGL,DONGL,LuC,etal.MethylationofSDC2/TFPI2andItsDiagnosticValueinColorectalTumorousLesions[J].FrontiersinMolecularBiosciences,2021,8
[39] 韩冰,申玉翠,王慧,等.粪便Vimentin和SFRP2甲基化在结直肠癌筛查中的作用[J].胃肠病学和肝病学杂志,2020,29(5):561-566.
[40] LINDGE,AHLQUIST T, KOLBERG M, et al. Hypermethylated MAL gene-a silent marker of early colon tumorigenesis[J].Journal of Translational Medicine,6,1(2008-03-17), 2008, 6(1):13-24.
[41] SHEN L, KONDO Y, HAMILTON SR, et al. p14 methylation in human colon cancer is associated with microsatellite instability and wild-type p53[J].Gastroenterology, 2003, 124 (3):626-633.
[42] KAZUYA M,KAZUYUKI K,YOSHINORI I,etal. Hypermethylati on of the CDKN2A gene in colorectal cancer is associated with shorter survival[J]. Oncology Reports, 2003, 10(4): 935-938.
[43] ESTELLER M, HAMILTON SR, BURGER PC, et al. Inactivation of the DNA Repair Gene O6-Methylguanine-DNA Methyltransferase by Promoter Hypermethylation is a Common Event in Primary Human Neoplasia[J]. Cancer Research, 1999,59(4):793-797.
[44] FAN J, LI J, GUO S, et al. Genome-wide DNA methylation profiles of low- and high-grade adenoma reveals potential biomarkers for early detection of colorectal carcinoma[J]. Clinical Epigenetics,2020,12(1): 56
[45] SHEN Y, WANG D, YUAN T, et al. Novel DNA methylation biomarkers in stool and blood for early detection of colorec tal cancer and precancerous lesions[J]. Clinical Epigenetics, 2023,15(1).
[46] 国家食品药品监督管理总局医疗器械技术评审中心.体外诊断试剂产品注册技术评审报告:人类SDC2基因甲基化检测试剂盒(荧光PCR法)(CSZ1800035)[R/OL].[2018-11-13].https: //www.cmde.org.cn/CL0116/8094.html.
[47] MAL,QING,GAIF,etal.A novel method for early detecti on of colorectal cancer based on detection of methylation of two fragments of syndecan-2 (SDC2) in stool DNA[J]. BMC Gastroenterology,2022,22(1):1-10.
[48] SHI ZY, CHEN LP, LI BX, et al. Comparative analysis of different fecal DNA extraction methods[J]. Chinese Journal of Biotechnology,2022,38(9):3542-3550.
[49] WANG J, LIU S, WANG H, et al. Robust performance of a novel stool DNA test of methylated SDC2 for colorectal cancer detection: a multicenter clinical study[J]. Clinical Epigenetics,2020,12(1):162-174.
[50] WANG DY, HE KX, HUANG Y, et al. A New Method for the Detection of Colorectal Cancer and the Precancerous Lesions: Occult Blood Testing Combination with Promoter Methylation in the Fecal Sample[J].Journal of Cancer,2021,12(2): 335-342.
[51] IMPERIALE TF, RANSOHOFF DF, ITZKOWITZ SH, et al. Multitarget stool DNA testing for colorectal-cancer screening [J].The New England journal of medicine,2014,370(14):1287- 1297.
[52] 马志刚,朱晓麟,马丽红.基于多靶点粪便FIT-DNA联合检测技术的结直肠癌早期筛查结果分析[J].中华结直肠疾病电子杂志,2019,8(06):616-621.
[53] KATSMANE, ORLANSKI S, MARTIGNANO F, et al. Detecting cell-of-origin and cancer-specific methylation features of cell-free DNA from Nanopore sequencing[J]. Genome Biology, 2022,23(1):1-25.
[54] LEE I, RAZAGHI R, GILPATRICK T, et al. Simultaneous profiling of chromatin accessibility and methylation on huma n cell lines with nanopore sequencing[J]. Nature Methods, 2020,17,1191-1199.
[55] 贾哲,吴晓滨.肠道微生物群在肿瘤中的作用和机制研究进展[J].消化肿瘤杂志:电子版,2023,15(2):160-165.
[56] 陈星,姜泊,迪吉.肠道菌群对早期结直肠癌筛查的研究进展[J].消化肿瘤杂志:电子版,2022,14(3):262-267.
[57] EVELIEND, TANIS PJ, VLEUGELS JLA, et al. Colorectal cancer[J]. Lancet (London, England), 2020, 2019年394卷10207期:1467-1480.
[58] WILLETT CG, CHANG DT, CZITO BG, et al. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer[J].Nature2012.(5);487: 330-37.
[59] FENNELL LJ, JAMIESON S, MCKEONE D, et al. MLH1-93G/a polymorphism is associated with MLH1 promoter methylation and protein loss in dysplastic sessile serrated adenomas with BRAF V600E mutation[J]. Bmc Cancer,2018,18(1):35.
[60] FARZANEHFAR M, VOSSOUGHINIA H, JABINI R, et al. Evaluation of methylation of MGMT (O⁶-methylguanine-DNA methylt ransferase) gene promoter in sporadic colorectal cancer[J]. Dna & Cell Biology,2013,32(7):371-377.
[61] LEGGETT B, WHITEHALL V, Role of the serrated pathway in colorectal cancer pathogenesis[J].Gastroenterology, 2010, 138(6):2088-2100.
[62] 潘程宇,曹俊,季兴,等.实时荧光定量PCR和甲基化特异性PCR检测结直肠癌 APC、MLH1基因甲基化状态[J].胃肠病学,2011,16(002):77-81.
[63] 蔡克银,徐梅华,王晓.检测粪便DNA中hMLH1基因甲基化对老年性结直肠癌早期诊断的意义[J].联勤军事医学,2017,31(12):814-817.
[64] 高文仓,张月蒙.胰岛素样生长因子结合蛋白相关蛋白1基因甲基化检测联合粪便潜血定量试验在结直肠癌中的诊断价值[J].中国医药,2021,16(6):886-889.
[65] GUINNEYJ, DIENSTMANN R, WANG X, et al. The consensus molecular subtypes of colorectal cancer[J]. Nature medicine, 2015,21(11):1350-1356.
[66] LEE MS, MENTER DG, KOPETZ S. Right Versus Left Colon Cancer Biology: Integrating the Consensus Molecular Subtyp es[J].Journal of the National Comprehensive Cancer Network, 2017,15(3):411-419.
[67] SANO Y,BYEON JS,LI XB,et al. Colorectal cancer screen ing of the general population in East Asia[J]. Dig Endosc, 2016, 28(3):243-249.
[68] ISLAMI F,WARD EM,SUNG H,et al. Annual report to the nation on the status of cancer,part 1:national cancer stati stics[J],Journal of the National Cancer Institute,2021,113(12),1648-1669.
[69] XU JF, RONG L, GU F, et al. Asia-Pacific Colorectal Screening Score Combined with Stool DNA Test Improves the Detection Rate for Colorectal Advanced Neoplasms[J]. Clinical gastroenterology and hepatology: the official clinical prac tice journal of the American Gastroenterological Association, 2023,21(6):1627-1636.
[70] RUBIN J S, BARSHIISHAT-KUPPER M, FEROZE-MERZOUG F,et al. Secreted WNT antagonists as tumor suppressors: pro and con[J]. Frontiers in Bioscience, 2006,11(11):2093-2105.
[71] LEE JL, LIN CT, ChUEH LL, et al. Autocrine/paracrine SFRP2 induces cellular resistance to apoptosis: A possible mechanism of mammary tumorigenesis[J]. Journal of Biological Chemistry,2004,279(15):14602-14609.
[72] BOVOLENTA P, ESTEVE P, RUIZ JM, et al. Beyond Wnt inh ibition: new functions of secreted Frizzled-related proteins in development and disease[J].J Cell Sci,2008,121(Pt6):737-746.
Copyright © 2024 肖白丁, 尧晨光, 李涵泺, 胡康洪
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License